Skip to main content
Thursday 21 May 2026
BlueSky linkedin youtube
header links
  • Get Newsletters
  • Media Kit
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Equity and Sustainability
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Patients & Partnerships
    • GLP-1
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • Spotlight on
    • ASCO
    • BIO-Europe
    • C-Suite Innovators
    • ESMO
    • Frontiers Health
    • JP Morgan
    • Global Policy Insights
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
youtube linkedin BlueSky
Sign in

Keytruda

News
Merck&Co_photo

Merck, Eisai get triple approvals for Keytruda/Lenvima combi...

News
Keytruda

Keytruda combo cleared as first-line kidney cancer treatment...

News
NICE1

MSD’s Keytruda plus chemo backed by NICE for lung cancer

News
KEYTRUDA is a prescription medicine used to treat a kind of skin cancer called melanoma

Keytruda 100mg/4mL Vial and Carton
2015

Study resurrects Merck’s hopes for Keytruda in breast cancer

News
Merck claims a brace of head and neck cancer approvals

Merck claims a brace of head and neck cancer approvals

Merck & Co/MSD has done the double in head and neck cancer with a pair of FDA approvals for Keytruda in newly diagnosed patients on the same day.

News
Keeping up the PACE at the Scottish Medicines Consortium

SMC approves medicines for breast cancer, skin cancer, schiz...

The Scottish Medicines Consortium (SM

  • Load more results

Editor's Picks

  1. BMS signs $15.2bn R&D alliance with China's Hengrui
  2. UK Health Secretary resigns, sparking leadership speculation
  3. Reports: Makary out, Diamantas in as FDA commissioner
  4. EU agrees plan to tackle essential medicine shortages
  5. Clock starts ticking on UK's single patient record plan
News
Lilly's 'triple G' retatrutide aces crucial obesity trial

Lilly's 'triple G' retatrutide aces crucial obesity trial

Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png
Digital
Discover a new era of healthcare panel engagement
Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • Axtria Ignite 2025
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Get Newsletters

 
 
youtube linkedin BlueSky
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company